an be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov
or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)
This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Cougar Biotechnology, Inc. Johnson & Johnson has filed a tender offer statement with the SEC, and will mail an offer to purchase, forms of letter of transmittal and related documents to Cougar Biotechnology shareholders. Cougar Biotechnology will file with the SEC, and will mail to Cougar Biotechnology shareholders, a solicitation/recommendation statement on Schedule 14D-9. These documents contain important information about the tender offer and shareholders of Cougar Biotechnology are urged to read them carefully when they become available.
These documents will be available at no charge at the SEC's website at www.sec.gov. The tender offer statement and the related materials may be obtained for free by directing a request by mail to Georgeson Inc., 199 Water Street, 26th Floor, New York, New York 10038 or by calling toll-free (877) 278-9667. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge by directing a request to Johnson & Johnson at www.jnj.com, or Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933, Attn: Corporate Secretary.
Page: 1 2 3 4 Related biology technology :1
. Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.2
. Simbionix and Johnson & Johnson LLC Announce a Distribution Agreement for Russia and the CIS Countries3
. Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.4
. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.5
. Johnson & Johnson Announces Definitive Agreement to Acquire Omrix6
. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer7
. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate8
. Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production9
. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research10
. Migenix averts proxy contest; reaches agreement with DJohnson holdings11
. Craig Johnson Joins Ardea Biosciences Board of Directors